Sobi's TRYNGOLZA Gains CHMP Nod for Severe Hypertriglyceridemia
Event summary
- CHMP recommends approval of TRYNGOLZA (olezarsen) for severe hypertriglyceridemia (sHTG) in the EU, ahead of schedule.
- Phase 3 CORE and CORE2 studies showed a 72% reduction in triglyceride levels and 85% reduction in acute pancreatitis events.
- European Commission decision expected in Q4 2026; TRYNGOLZA would be the first RNA-targeted therapy for sHTG in the EU.
- Sobi holds exclusive commercialization rights outside the US, excluding Canada and China, under a license agreement with Ionis.
The big picture
Sobi's positive CHMP opinion for TRYNGOLZA marks a significant milestone in the treatment of severe hypertriglyceridemia, a condition affecting approximately 700,000 people in the EU5 with triglyceride levels ≥880 mg/dL. The approval would solidify Sobi's leadership in rare disease therapies and expand its portfolio of RNA-targeted treatments. The strategic collaboration with Ionis Pharmaceuticals underscores the growing importance of targeted RNA therapies in addressing metabolic disorders.
What we're watching
- Regulatory Timing
- Whether the European Commission will approve TRYNGOLZA by the end of Q4 2026, as anticipated.
- Commercial Strategy
- How Sobi plans to position TRYNGOLZA in the EU market, given its first-to-market status for RNA-targeted therapies in sHTG.
- Clinical Impact
- The long-term efficacy and safety of TRYNGOLZA in reducing acute pancreatitis events and improving patient outcomes.
